The financials
Ascendis Pharma A/S by the numbers
Ascendis Pharma A/S (ASND) reported revenue of €248M in Q4 2025 (quarter ended December 31, 2025), up 42% from the same quarter a year earlier. That came with a gross margin of 90% and net loss of €34M. For the full year FY2025, revenue was €720M (+98% year on year) and net income −€228M.
| Income statement | Q4 2025 | Q4 2024 | Change |
|---|---|---|---|
| Revenue | €248M | €174M | +42% |
| Gross profit | €224M | €160M | +40% |
| Operating income | €9.9M | €383K | +2484% |
| Net income | −€34M | −€38M | n/a |
| Diluted EPS | n/a | −€0.60 | n/a |
Biotechnology
Ranks #59 of 145 by Smart Score